Momenta Pharmaceuticals Announces Oral and Poster Presentations Relating to Novel Autoimmune Programs at EULAR 2015

CAMBRIDGE, Mass., June 4, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that new data from studies of the Company's novel autoimmune programs will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2015 Annual Meeting in Rome, Italy.

Poster Presentation:

"Targeting the Neonatal Fc Receptor (FcRn) to Mediate Autoantibody Clearance in IgG-driven Autoimmune Disease"
Date/Time: Thursday, June 11, 2015 at 12:00-1:45pm CET

  • This poster summarizes the identification, characterization, and in vivo effects of Anti-FcRn (M281), a fully-human monoclonal antibody that binds the neonatal Fc receptor, thereby increasing IgG catabolism and facilitating autoantibody clearance. M281 is in preclinical development and the Company expects to continue to advance this product candidate with a goal of entering the clinic in late 2016.

Oral Presentation:

"High-resolution, Integrated Molecular Profiling Reveals Persistent Inflammation in Kawasaki Disease Patients with Coronary Artery Aneurysms"
Date/Time: Friday, June 12, 2015 during the 10:30am-12:00pm CET session

  • As part of the Company's research on intravenous immunoglobulin (IVIG), Momenta applied its high-resolution biological analytics to identify biologies impacted by treatment, and biologies associated with clinical resolution of Kawasaki disease. This oral presentation describes Momenta's approach to identifying biomarkers associated with sub-clinical disease activity and provides insights into the mechanism of action of IVIG in this disease.

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural and functional analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at, which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to its beliefs and intentions related to the marketing approval, launch and commercialization of our novel autoimmune drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Relations: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 Media Relations: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060

Source:Momenta Pharmaceuticals